Zobrazeno 1 - 10
of 668
pro vyhledávání: ''
Autor:
Rohit Mehra, Emmanuel S. Antonarakis, Javed Siddiqui, Felix Y. Feng, Costantine Albany, Przemyslaw Twardowski, Bruce Montgomery, Yi-Mi Wu, Karen E. Knudsen, Maha Hussain, Young E. Whang, Mark N. Stein, Dan R. Robinson, Daniel H. Shevrin, Arul M. Chinnaiyan, Megan E.V. Caram, Lakshmi P. Kunju, Walter M. Stadler, Kathleen A. Cooney, Xuhong Cao, Stephanie Daignault-Newton, Robert J. Lonigro, Paul G. Corn, David Smith, Scott A. Tomlins
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 10
Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response. Patients a
Autor:
Peter Kamper, Alexander Lindholm d'Amore, David W. Scott, Joseph M. Connors, Randy D. Gascoyne, Marcel Nijland, Sohrab P. Shah, Christian Steidl, Anja Mottok, Anke van den Berg, Stephen Hamilton-Dutoit, Fong Chun Chan, Alina S. Gerrie, Kerry J. Savage, Maryse M. Power, Arjan Diepstra, Francesco d'Amore
Publikováno v:
Chan, F C, Mottok, A, Gerrie, A S, Power, M, Nijland, M, Diepstra, A, van den Berg, A, Kamper, P, d'Amore, F, d'Amore, A L, Hamilton-Dutoit, S, Savage, K J, Shah, S P, Connors, J M, Gascoyne, R D, Scott, D W & Steidl, C 2017, ' Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma ', Journal of Clinical Oncology, vol. 35, no. 32, pp. 3722-3733 . https://doi.org/10.1200/JCO.2017.72.7925
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Purpose Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discover novel and robust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT). Materials and Methods We performed
Autor:
James H. Doroshow, DW Visscher, Matthew P. Goetz, Stephanie L. Safgren, Vera J. Suman, Andrew T. Ralya, Michael A. Mahr, Tufia C. Haddad, James N. Ingle, Benjamin R. Kipp, Jerry M. Collins, Joel M. Reid, Charles Erlichman, Zachary R. Chalmers, Garrett M. Frampton, Alex A. Adjei, John R. Hawse, Don W. Northfelt, Travis J. Dockter, Minetta C. Liu, Mary J. Kuffel, Sarah A. Buhrow, Matthew M. Ames, John L. Black, Howard Streicher, Renee M. McGovern
Publikováno v:
Journal of Clinical Oncology. 35:3391-3400
Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity.
Autor:
Paul G. Richardson, Hervé Avet-Loiseau, Benoit Dupas, Martine Escoffre-Barbe, Aurore Perrot, Eric Frampas, Caroline Bodet-Milin, Lotfi Benboubker, Michel Attal, Thierry Facon, Gerald Marit, Jean-Richard Eveillard, Florence Caillon, Cyrille Hulin, Véronique Dorvaux, Lionel Karlin, Carine Chaleteix, Denis Caillot, Anne-Marie Stoppa, Brigitte Pegourie, Philippe Moreau, Kamel Laribi, Laurent Garderet, Jean-Michel Nguyen, Nikhil C. Munshi, Kenneth C. Anderson, Aurélie Gaultier, Margaret Macro, Françoise Kraeber-Bodéré
Publikováno v:
Journal of Clinical Oncology. 35:2911-2918
Purpose Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We conducted a prospective trial in patients with MM aimed at comparing MRI and PET-CT
Autor:
Stephanie Harmon, Glenn Liu, William L. Dahut, Timothy Perk, Robert Jeraj, Christie Lin, Jens Eickhoff, Andrea B. Apolo, Steven M. Larson, John L. Humm, Peter L. Choyke, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 35:2829-2837
Purpose [18F]Sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) is a promising radiotracer for quantitative assessment of bone metastases. This study assesses changes in early NaF PET/CT response measures in metastatic
Autor:
Greg Yothers, Yan Lin, Takeharu Yamanaka, Michael Crager, Calvin Chao, Alan P. Venook, Frederick L. Baehner, Takayuki Yoshino
Publikováno v:
Journal of Clinical Oncology. 39:3599-3599
3599 Background: The 12-gene Oncotype DX Colon Recurrence Score assay is a clinically validated genomic assay that evaluates recurrence risks in stage II and stage III colon cancer patients independent of clinical-pathologic features. Improved colon
Autor:
Marion Joy, Rim S. Kim, Melanie Finnigan, Greg Yothers, Nan Song, Jennifer Marie Suga, Ying Wang, Norman Wolmark, Naoyuki G. Saito, Ashok Srinivasan, Peter C. Lucas, Nicholas J. DiBella, Soonmyung Paik, Katherine L. Pogue-Geile, Judith O. Hopkins, Samuel A. Jacobs, Carmen J. Allegra
Publikováno v:
Journal of Clinical Oncology. 39:3516-3516
3516 Background: The purpose of this study was to quantify different molecules of TIME including T cells, macrophages, and immune checkpoint proteins (ICPs), and determine their association with clinical outcomes and treatment benefit in pts enrolled
Autor:
Janice M. Walshe, Hanna Bandos, Shiyu Wang, Andrea Menicucci, M. William Audeh, Laura van 't Veer, Priya Rastogi, Peter C. Lucas, Eleftherios P. Mamounas, Louis Fehrenbacher, Shaker R. Dakhil, Adam Brufsky, Charles E. Geyer, Gamini S. Soori, Soonmyung Paik, Stephen Chia, Norman Wolmark, Mark L. Graham, Sandra M. Swain, Jia-Perng Jennifer Wei
Publikováno v:
Journal of Clinical Oncology. 39:502-502
502 Background: The 70-gene MammaPrint (MP) assay predicts risk of distant recurrence (DR) in hormone-receptor positive early-stage breast cancer and classifies cancers as Low Risk or High Risk. NSABP B-42 evaluated ELT in patients (pts) who had comp
Autor:
Charles A. Powell
Publikováno v:
Journal of Clinical Oncology. 35:705-708
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and
Autor:
J. Jack Lee, Lixia Diao, John V. Heymach, Ferdinandos Skoulidis, Sanjay Gupta, Ximing Tang, Waun Ki Hong, Kevin R. Coombes, David J. Mauro, Ignacio I. Wistuba, Vassiliki A. Papadimitrakopoulou, Vincent A. Miller, Ja Seok Koo, Caimiao Wei, Eric H. Rubin, Julie G. Izzo, Li Shen, Scott N. Gettinger, Anne S. Tsao, Neda Kalhor, Jing Wang, Lauren Averett Byers, S. Andrew Peng, Alda L. Tam, Don L. Gibbons, Frank V. Fossella, Sarah B. Goldberg, Roy S. Herbst
Publikováno v:
Journal of Clinical Oncology. 34:3638-3647
Purpose By applying the principles of real-time biopsy, biomarker-based, adaptively randomized studies in non–small-cell lung cancer (NSCLC) established by the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE)